Letter to the Editor
Identification of Hymenoptera venom–allergic patients with negative specific IgE to venom extract by using recombinant allergens

https://doi.org/10.1016/j.jaci.2013.09.047Get rights and content

References (7)

There are more references available in the full text version of this article.

Cited by (42)

  • CAP superfamily proteins from venomous animals: Who we are and what to do?

    2022, International Journal of Biological Macromolecules
  • Venom allergy evaluation, diagnosis, and treatment

    2022, Allergic and Immunologic Diseases: A Practical Guide to the Evaluation, Diagnosis and Management of Allergic and Immunologic Diseases
  • A WAO — ARIA — GA<sup>2</sup>LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

    2020, World Allergy Organization Journal
    Citation Excerpt :

    PAMD@ is helpful to discriminate between true allergy to different venoms and cross-sensitization, allowing physicians to correctly identify the risk and to optimize venom selection for immunotherapy.5,74 PAMD@ is also useful in identifying patients with Hymenoptera venom-induced anaphylaxis who have negative test results to whole-venom extracts.236,237 PAMD@ with CCD-free allergens and CCD markers is always preferable.

View all citing articles on Scopus

This work was supported by the “Hochschulwissenschaftsprogramm” (HWP), “Kommission Klinische Forschung” (KKF) of the Technical University Munich, and the Christine Kühne – Center for Allergy Research and Education (CK-CARE). L.C. and D.P. were supported by a scholarship of Bayerische Forschungsstiftung.

Disclosure of potential conflict of interest: U. Darsow has consultant arrangements with Bencard and Leo and has received payment for lectures from Bencard and Novartis. R. Bredehorst is cofounder of PLS-Design Gmbh, which owns patent rights for Api m 3, Api m 5, and Ves v 3. J. Ring has received research support from ALK-Abelló, Allergopharma, Almirall-Hermal, Astellas, Bencard, Biogen-Idec, Galderma, GlaxoSmithKline, Leo, Merck Sharp Dohme, Novartis, Phadia, PLS Design, and Stallergenes. E. Spillner is cofounder of PLS-Design GmbH. M. W. Ollert has consultant arrangements with Siemens Healthcare Diagnostics and Hitachi Chemical Diagnostics, has received payment for lectures from Phadia/Thermo Fisher, has received payment for education presentations from Siemens Healthcare Diagnostics, and is the scientific cofounder of the University of Hamburg biotech spin-off PLS-Design GmbH (Hamburg, Germany). The rest of the authors declare that they have no relevant conflicts of interest.

View full text